67 results about "Benign tumours" patented technology

The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and / or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and / or treating, and for preventing and / or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia. The present invention further relates to methods for inducing the regeneration of cells, tissues, organs and organic systems such as the circulatory, nervous and endocrine systems. Finally, the present invention relates to methods for restoring immune response in an animal, in particular a human being.

The present invention relates to kinase modulators of the naphthyridine type and to the preparation and use thereof as medicaments for the modulation of misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine and serine / threonine kinases and for the treatment of malignant or benign tumours and other disorders based on pathological cell proliferation, such as, for example, restenosis, psoriasis, arteriosclerosis and cirrhosis of the liver.

The present invention relates to the use of cannabidiol (CBD) for the treatment of tumours associated with Tuberous Sclerosis Complex (TSC). In particular the CBD was able to decrease the number and size of marker cells, pS6, in a zebrafish model of TSC. This is5 suggestive of a disease modifying effect whereby treatment with CBD could result in the reduction or prevention of the benign tumours that occur in TSC patients. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially 10 removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD. In use the CBD is given concomitantly with one or more other drugs used in the treatment of TSC. Such drugs may include rapamycin and / or everolimus.

The invention discloses a three-way-decision-based liver tumor CT image classification method. A classifier is trained; image preprocessing and feature extraction are carried out on a marked liver CT image training sample to form a feature vector; rule extraction is carried out by using an attribute reduction method to form a knowledge base, thereby providing a basis for follow-up case classification diagnoses. T-be-classified cases are processed image pretreatment to extract liver regions, hepatic vessels, and liver tumors; 14 case features are calculated; the case feature values are inputted into a three-way-decision-based classifier; and then cases are classified into three types: a benign tumor, a malignant tumor, and an uncertain tumor. Therefore, a doctor can make different therapeutic regimens for different tumor types.

The invention provides a traditional Chinese medicine composition for treating lobular hyperplasia of mammary glands and breast tumor. The traditional Chinese medicine composition consists of the following components in certain parts by weight: Chinese thorowax root, nutgrass galingale rhizome, Chinese angelica, Szechuan lovage rhizome, danshen root, pangolin scales, zedoary rhizome, milkvetch root, Indian buead, motherwort herb, common burreed rhizome, deerhorn, dried tangerine peel, green tangerine peel, peach seeds, bulb of thunberg fritillary, fruit-spike of common selfheal, frankincense, tangerine seeds, licorice root, cowherb seed, safflower, turmeric root-tuber, towel gourd vegetable sponge, cochinchnese asparagus root, Mongolian dandelion herb, pseudobulb of appendiculate cremastra, corydalis tuber, beautiful sweetgum fruit, honeysuckle flower, coptis chinensis, figwort root, pinellia tuber and glossy privet fruit. The traditional Chinese medicine composition provided by the invention can be used for treating diseases such as lobular hyperplasia of mammary glands, breast benign tumor and uterine myoma, is significant in effect, cannot cause toxic or side effects, ensures that the effective treatment rate can reach 96%, and is not easy to cause recurrence.

The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.

The invention provides a breast cancer histopathological type classification method based on generative adversarial network screening image blocks, which comprises the following steps: acquiring a breast cancer histopathological type image data set, and further comprises the following steps: preprocessing breast cancer histopathological type images; enabling the generative adversarial network to screen normal regions in the benign image blocks and the malignant image blocks; enabling the generative adversarial network to screen benign regions in the malignant image blocks; and classifying thebreast cancer histopathological images by using a convolutional neural network based on cyclic dense connection. According to the invention, the improved unsupervised generative adversarial network isadopted to learn the data distribution of the normal pathology image and the benign tumor pathology image respectively, so that the benign tumor area and the normal area in the malignant tumor pathology image and the normal area in the benign tumor pathology image can be screened; and the possibility is provided for assisting doctors to diagnose the illness state more accurately and more quicklyto the maximum extent.

The invention discloses a breast tumor ultrasonic image classification method based on a three-dimensional convolutional neural network, and relates to the technical field of computer image processing. The method comprises the specific steps that data preprocessing is carried out, a training set is used for training a proposed three-dimensional convolutional neural network, benign tumors are marked as 0, and malignant tumors are marked as 1; testing the trained model by using a test set, and finally outputting the probability of benign and malignant tumors through a softmax function, extracting regions of interest, and performing tumor probability estimation on each region of interest by using a three-dimensional convolutional neural network; diversity, namely complexity, of breast cancerimages causes certain difficulties to diagnosis of doctors, the misdiagnosis rate of tumors can be effectively reduced through automatic classification of breast tumor ultrasonic images based on deeplearning, and meanwhile reliable reference bases can be provided for diagnosis of the doctors.

The invention relates to a method and a device for screening, diagnosing or risk grading of ovarian cancer. Specifically, the invention relates to a method and a device for screening, diagnosing or risk grading of ovarian cancer by constructing a decision tree model by using high-throughput sequencing and CA-125 level; and more specifically, the invention relates to construction of the decision tree model by using high-throughput sequencing and CA-125 level, and training of the model for screening and detection of ovarian cancer; and therefore, the clinical problems of difficult discovery of the ovarian cancer due to hidden early ovarian cancer symptoms, difficulty in judging whether masses are ovarian cancer or benign ovarian tumors due to undetermined ovarian masses in property, and thepossibility of negative tumor markers accompanied by malignant pelvic cavity masses are solved from the molecular biology level. According to the method and the system, the possible ovarian cancer canbe found through one-time detection.

The invention provides a construction method and device of benign and malignant tumor identification model, and the method comprises the steps: taking a plurality of known benign tumor samples and malignant tumor samples as a training set, and obtaining TCR clone types and CDR3 segments of the samples in the training set; counting and calculating the occurrence frequency of the CDR3 section, and then recoding the CDR3 section through Kmer interruption; carrying out data dimension reduction processing on the Kmer frequency data obtained after CDR3 recoding; associating benign and malignant information of a known tumor sample in the training set with the Kmer data after data dimension reduction, and performing model training by using a machine learning algorithm to obtain a benign and malignant tumor identification model. The benign and malignant tumor identification model constructed by the construction method is used for carrying out benign and malignant tumor identification on unknowntumor samples, can identify benign and malignant tumor samples of different types, and meets the requirements of broad spectrum and specificity.

The invention belongs to the technical field of biological medicines, relates to novel medicinal applications of dopamine I receptor agonists, and in particular relates to novel applications of the dopamine I receptor agonists in preparing tumor treatment medicines. The dopamine I receptor agonists comprise DRD1 and DRD5 agonists, and are selected from SKF83959 or SKF38393 compounds. The cell culture and drug intervention experiments prove that the dopamine receptor agonist SKF83959 can inhibit the mTOR pathway for inducing autophagy, and increase ROS for prompting the cell death from the in-vitro and in-vivo levels, so that the growth of benign or malignant tumor can be inhibited. The dopamine I receptor agonists SKF83959 and SKF38393 can be used for preparing the medicines for treating tumors, wherein the tumors comprise the benign tumour including pituitary adenoma and the malignant tumors including malignant glioma, colon cancer, liver cancer, stomach cancer and the like.

A Chinese and western composite medicine for treating neoplastic diseases is characterized by comprising Chinese herbal medicinal ingredients and a western medicinal ingredient which are mixed, the Chinese herbal medicinal ingredients include 5 polyzyme tablets and a stomach invigorating and digestion aiding tablet, each polyzyme tablet comprises pepsin, trypsin, pancreatic lipase and amylopsin, and the stomach invigorating and digestion aiding tablet comprises radix pseudostellariae, tangerine peels, Chinese yam, (roasted) malt and hawthorn; the western medicinal ingredient is ceftriaxone sodium injection solution; and the weight of each polyzyme tablet is 0.313g, the total weight of the polyzyme tablets is 1.57g, the weight of the stomach invigorating and digestion aiding tablet is 0.8g, the weight of the ceftriaxone sodium injection solution is 0.75g, and the Chinese herbal medicinal ingredients and the western medicinal ingredient are combined to form the prescription. The Chinese and western composite medicine for treating the neoplastic diseases is particularly used for suppressing and killing pathogenic bacteria capable of causing benign tumor and malignant tumor infection of tissue cells of a human body, the composite medicine is directly dripped into the oral cavity or an affected part of the human body when the human body suffers from the tumor infection, and 3-4 drops of the composite medicine are applied every time. The Chinese and western composite medicine has few side effects, becomes effective within 30 minutes and does not injure the liver, the brain and the kidneys of the human body.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

The invention discloses a diagnostic reagent for serum of early breast cancer and a detection method thereof. A ferritin heavy chain 1 (FTH1) or an FTH1 united heterogeneous nuclear ribonucleoprotein F (hnRNPF) is adopted by the diagnostic reagent to serve as a tumor marker, thus, the diagnostic reagent is capable of detecting an FTH1 antibody in the serum to be detected, or the corresponding antibody of the FTH1 and the hnRNPF, and is used for early diagnosis of the breast cancer or postoperative curative effect monitoring. The reagent disclosed by the invention is verified through the application of the serum of patients with the breast cancer, breast benign tumor and other kinds of cancer (not including the breast cancer) and normal people. The diagnostic reagent for the serum of the early breast cancer is used for the early diagnosis and differential diagnosis of the breast cancer, aims to improve the sensitivity, the specificity and the accuracy of the early diagnosis of the breast cancer and is more beneficial to the diagnosis and the treatment of the patients with the breast cancer, thereby, the problem that the traditional tumor marker of the breast cancer is not ideal is solved, and the goal of improving the sensitivity and the accuracy of the early diagnosis of the breast cancer is achieved.

The invention relates to a specific protein marker for ovarian cancer diagnosis and a preparation method of the protein marker. The specific protein marker comprises the components including C reactive protein in serum exosome, solute transport protein family 11 member 2, ubiquitin-like PHD and ring finger domain protein 1. The preparation method comprises the following steps of protein extraction, pancreatin enzymolysis, TMT labeling, HPLC grading, liquid chromatography-mass spectrometry analysis, database search, protein identification, protein differential expression analysis, protein annotation and bioprotein marker screening. The protein marker has the advantages that (1) the marker has relatively high sensitivity and specificity; (2) ovarian malignant tumors can be distinguished frombenign tumors / healthy people; and (3) the preparation process is clear, the operability is high, and the repeatability is high.

The invention discloses a human benign phyllodes tumor cell line GLK-1010, which is preserved in China Center for Type Culture Collection, wherein the preservation address is Wuhan University, Wuhan,China, and the preservation number is C2018235. The invention also discloses applications of the human benign phyllodes tumor cell line GLK-1010 as a cell model in research of tumor occurrence and development mechanism and in screening of antitumor drugs. The human phyllodes tumor cell line GLK-1010 disclosed by the invention is established from the source of Chinese people, the line establishmenttime is short, the biological heredity is stable, no human benign phyllodes tumor cell line exists on the market at present, and by using the phyllodes tumor cell line as a research model, great helpcan be provided for knowing the pathogenesis of Chinese benign phyllodes tumor patients.

The invention discloses a composition and kit for methylation noninvasive early detection of ovarian cancer. The composition comprises target gene detection primers and internal reference gene detection primers, wherein target genes are CDH13, FOXD3, ZNF671, HOXA11, FBXO32 and OPCML. The detection primers for the genes not only comprise promoter regions of the genes, but also comprise coding regions of the genes, and multi-gene methylation regions are selected in the composition for joint detection, so that functional complementation is formed, the sensitivity of detecting the ovarian cancer is remarkably improved, and the detection primers have very high specificity for normal and ovarian benign tumors. The kit containing the detection composition can detect patients with the possibilityof the ovarian cancer in advance by utilizing a methylation detection technology through a molecular epigenetic means, so that prevention and treatment can be carried out in advance.

The invention provides a multi-information fused pathological image classification and recognition method and system. The method comprises the steps of pathological data management, pathological image preprocessing, pathological image recognition, cancerization area prediction and diagnosis report generation. The system is divided into a background management server and a pathology expert terminal. The management background server is used for expert personal information storage management, patient data storage and pathology image data management. The pathology expert terminal is responsible for hospital experts to upload pathology images and patient information, and classification and recognition of the pathology images are realized through a pre-trained deep neural network model. A pathological expert can audit a deep learning recognition result through the expert terminal and generate a diagnosis report. According to the invention, pathological conditions of the pathological images are judged and a tumor area is predicted through a deep learning method, a benign tumor result and a malignant tumor result are automatically predicted, the area where the tumor is located is visually displayed on the pathological images, a doctor is assisted in diagnosing the pathological images, and the diagnosis effect and efficiency are improved.

The invention discloses a benign and malignant mammary tumour serum specific protein and application thereof, belonging to the field of biological detection technique. The invention uses an SELDI-TOF-MS technique, establishes the fingerprint of serum protein between the benign mammary tumour patient and breast carcinoma patient, carries out the variation analysis and searches new protein markers, thus dividing the benign and malignant mammary tumour. As the SELDI-TOF-MS technique is used by the invention, mass spectrometric detection, comparison and analysis are carried out on the serum of the peripheral blood of benign and malignant mammary tumour patients from the point of view of proteomics, thus establishing effective mammary tumour serum protein fingerprint which is used for the risk evaluation method used when the nasopharyngeal carcinoma is detected and distinguished outside the body. The method is a detection method with the sensitiveness and specificity better than that of the traditional method.

Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.

A three step method for selection and testing of compounds inhibiting clonal cell growth, consisting of 1) screening for substances that inhibit clonal growth in a culture, 2) in the same culture, testing whether a high local cell concentration (collocation) will decrease the inhibiting effect of such substances on clonal cell growth and 3) testing if export of metastatic cells from a tumour site could be locked by such substances. It should then be possible to decrease or even abolish the development of malignant disease or metastasis from primary tumours and development of benign tumours including atheromas in arteries. The method may also detect compounds that increase clonal growth. These compounds might possess carcinogenic properties or could be used for stimulation of a failing immune system.

The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.

The invention discloses a method for preparing antitumor traditional Chinese medicine tablets. The antitumor traditional Chinese medicine tablets are mainly prepared from the raw materials in parts by weight: 15 parts of rhizoma sparganii, 15 parts of spatholobus stem, 15 parts of slender dutchmanspipe root, 20 parts of astragalus root, 20 parts of barbat skullcap, 30 parts of valeriana jatamansi, 50 parts of hericium erinaceus, 1 part of leech, 1 part of cantharides, 1 part of dried wood-louse, 1 part of dung beetle, 1 part of centipede, 1 part of prepared turtle shell and 1 part of dried toad skin. According to the antitumor traditional Chinese medicine tablets, ingredients are comprehensive, complement one another and are used for strengthening the body resistance and fostering the root, repairing tissue cell regeneration and reversing disease cells to normal, and thus, benign tumors can be effectively treated; the traditional Chinese medicine has the advantages of convenience in preparation and use, safety and no toxic and side effects, thereby being an ideal antitumor drug.

The invention provides tumor rehabilitation soup and a preparation method thereof, and relates to the technical field of prevention and treatment of tumor. The tumor rehabilitation soup is prepared from tendon soup, wherein the tendon soup is prepared from 10 to 15 parts of tendons of large hoofed animals, 1 to 2 parts of snails, 1 to 2 parts of fresh water fish skin and 55 to 60 parts of water through decocting; for patients in different symptoms, a process of gradually adding the dosage from 0.1 L to 0.75 L every day is adopted, effective control on the tumor is finally realized, and the treatment effect is achieved. According to the tumor rehabilitation soup provided by the invention, daily diet is used as a dietary therapy formula, the nutrient requirements of a body are ensured, meanwhile, good prevention and treatment effects on benign tumor and cancer are obtained, and the pain of the patients is relieved; the tumor rehabilitation soup has the advantages that raw materials are easy to obtain, the cost is low, quick effects can be obtained, no pain exists, and the like; the patients get rid of the pain that a chemoradiotherapy surgery is large in side effects and an organism is easy to damage, the life quality of the patients can be effectively increased, the natural service life of the patients can be prolonged, and good social benefit is obtained.

The use of hydrochloric acid in the pharmaceutical field for tumorous tissue coagulation and necrosis is disclosed. The effect hydrochloric acid is preferable to the effects of other medicaments. Hydrochloric acid can be used for treating any noumenal tumour, including primary therioma, metastatic theioma, benign tumour, and also for destructing nerve to treat cancerous pain. Hydrochloric acid can be used for the manufacture of a medicament for the curative treatment of tumors.

The invention belongs to the technical field of medical image analysis, and particularly relates to a computer-aided diagnosis and treatment system based on an ovarian tumor benign and malignant prediction model. The system executes the following steps: S1, acquiring an ovary image and a corresponding tumor marker; s2, inputting the ovarian image and the corresponding tumor marker into a trained benign and malignant ovarian tumor prediction model, and outputting a tumor judgment result which is a benign tumor or a malignant tumor; wherein the ovarian tumor benign and malignant prediction model comprises an image-based tumor segmentation model, an image-based tumor classification model and a focus classification fusion prediction model. The prediction model obtained by the system is high in accuracy, and has better identification capability for special cases.

The invention discloses a nodule removing pill and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The pill with the diameter of 0.4-0.6 cm is prepared from fried immature bitter orange, radix paeoniae alba, rhizoma bolbostemmae, fructus perillae, euphorbia kansui, euphorbia pekinensis, semen brassicae, liquorice, honeysuckle stem, turtle shell and radix ranunculi ternati. The nodule removing pill prepared by the invention has the characteristics of strong pertinence, convenience in taking, no side effect and reasonable compatibility, clinical treatment shows that the traditional Chinese medicine pill is good in curative effect, quick in effect, safe and reliable to take and capable of treating both symptoms and root causes, and overcomes the defects of the existing treatment technology, and good news and hope are brought to patients suffering from various nodules such as thyroid nodules, breast nodules, pulmonary nodules and the like and Jakee's thyroiditis, thyroid tumors, renal cysts, hepatic cysts, breast benign tumors and malignant tumors.

A method for treating or reducing the incidence of recurrence of cancer, benign tumors or HPV-associated lesions, including skin cancer, and particularly squamous cell carcinoma (SCC) and basal-cell carcinoma, by administering one or more doses of HPV recombinant vaccine to a patient.

The invention discloses a Chinese herbal medicine formula for treating benign tumors in a lung and a preparation method thereof. The Chinese herbal medicine formula is prepared by the following raw materials in parts by weight: 8g of honeysuckle, 11g of angelica sinensis, 7g of root of rehmannia, 3g of wolfberry, 5g of radix semiaquilegiae, 6g of sparganium stoloniferum, 7g of pseudo-ginseng, 8g of safflower, 4g of toad, 11g of oldenlandia diffusa, 9g of myrrh, 12g of folium eriobotryae, 1g of gadfly and 5g of leech, wherein carcuma longa is carcuma longa fruit. Compared with western medicines or ordinary Chinese herbal medicines, the Chinese herbal medicine formula for treating benign tumors in the lung has good curative effect, becomes effective rapidly, has small side effects, is mild and can be taken for long time.